Key result
Reduced-dose prasugrel demonstrated comparable clinical efficacy to clopidogrel for major cardiovascular events in patients undergoing PCI, but was associated with a higher risk of minor bleeding.
Why the study?
The study sought to compare the clinical efficacy and safety of reduced-dose prasugrel versus clopidogrel in patients undergoing PCI.
Does reduced-dose prasugrel reduce major cardiovascular events compared to clopidogrel in adult patients undergoing percutaneous coronary intervention?
Meta-Analysis
Does reduced-dose prasugrel reduce major cardiovascular events compared to clopidogrel in adult patients undergoing percutaneous coronary intervention?
Reduced-dose prasugrel offers comparable ischemic protection to clopidogrel in patients undergoing PCI but is associated with an increased risk of minor bleeding.
Comparable ischemic outcomes support reduced-dose prasugrel as clopidogrel alternative post-PCI; extends RCT evidence while cautioning on minor bleeding risk.
Objectives: This systematic review and meta-analysis of randomized controlled trials (RCTs) compared the clinical efficacy and safety of reduced-dose prasugrel (loading dose: 20 mg; daily maintenance dose: 3.75 mg) and clopidogrel in patients undergoing percutaneous coronary intervention (PCI). Methods: PubMed, Embase, and the Cochrane Library database were searched for relevant articles from inception to March 8, 2021. Only RCTs that compared the clinical efficacy and safety of reduced-dose prasugrel and clopidogrel treatment in adult patients undergoing PCI were included. The primary outcome was the risk of major cardiovascular events (MACEs). Results: = 0%). In addition, cardiovascular-related death, all-cause death, nonfatal myocardial infarction, nonfatal stroke, revascularization, and stent thrombosis did not differ significantly between the two groups. Apart from a higher risk of minor bleeding in the study group, reduced-dose prasugrel had a similar bleeding risk to clopidogrel. Conclusions: The clinical efficacy of reduced-dose prasugrel is comparable to that of clopidogrel; however, the risk of minor bleeding should be considered when prescribing this regimen for patients undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2022) conducted a meta-analysis in percutaneous coronary intervention (PCI). Reduced-dose prasugrel vs. Clopidogrel was evaluated on major cardiovascular events (MACEs). Reduced-dose prasugrel demonstrated comparable clinical efficacy to clopidogrel for major cardiovascular events in patients undergoing PCI, but was associated with a higher risk of minor bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: